How to buy Kazia Therapeutics (KZA) shares

Learn how to easily invest in Kazia Therapeutics shares.

Kazia Therapeutics Limited
-A$0.02 (-1.61%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Kazia Therapeutics Limited is a biotechnology business based in Australia. Kazia Therapeutics shares (KZA) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Kazia Therapeutics has a trailing 12-month revenue of around $363,489. If you're looking to buy shares, check out the steps below.

How to buy shares in Kazia Therapeutics

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Kazia Therapeutics . Find the share by name or ticker symbol: KZA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kazia Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Kazia Therapeutics . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kazia Therapeutics stock price (ASX:KZA)

Use our graph to track the performance of KZA stocks over time.

Kazia Therapeutics shares at a glance

Information last updated 2021-07-28.
52-week range$0.5 - $1.88
50-day moving average $1.3065
200-day moving average $1.349
Target price$0.22
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.179

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
Finder Award
IG Share Trading
AUD $8 or 0.1%
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
AUD $5
ASX shares, US shares, ETFs
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
ThinkMarkets Share Trading
AUD $8
ASX shares, ETFs
$8 flat fee brokerage for CHESS Sponsored ASX stocks (HIN ownership), plus free live stock price data on an easy to use mobile app.
CMC Markets Stockbroking
AUD $11 or 0.1%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
Bell Direct Share Trading
AUD $15
ASX shares, mFunds, ETFs
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
Saxo Capital Markets (Classic account)
AUD $6.99
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.

Compare up to 4 providers

Is it a good time to buy Kazia Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Kazia Therapeutics price performance over time

Historical closes compared with the last close of A$1.27

1 month (2021-07-02) -3.79%
3 months (2021-05-04) -8.63%
5 years (2016-07-31) inf%

Kazia Therapeutics financials

Revenue TTM $363,489
Gross profit TTM $988,000
Return on assets TTM -26.94%
Return on equity TTM -58.95%
Profit margin 0%
Book value 0.251
Market capitalisation $165.3 million

TTM: trailing 12 months

Kazia Therapeutics share dividends

We're not expecting Kazia Therapeutics to pay a dividend over the next 12 months.

Have Kazia Therapeutics 's shares ever split?

Kazia Therapeutics 's shares were split on a 1:10 basis on 16 November 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kazia Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kazia Therapeutics shares which in turn could have impacted Kazia Therapeutics 's share price.

Kazia Therapeutics share price volatility

Over the last 12 months, Kazia Therapeutics 's shares have ranged in value from as little as $0.5 up to $1.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Kazia Therapeutics 's is 2.7003. This would suggest that Kazia Therapeutics 's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Kazia Therapeutics overview

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. It has collaboration agreements with St Jude Children's Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and the University of Newcastle. Kazia Therapeutics Limited also has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug paxalisib in primary central nervous system lymphoma; Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083; and Joan & Sanford I Weill Medical College of Cornell University for Phase II clinical study using Paxalisib in combination with ketogenic diet for glioblastoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform